Current guidelines for gene testing in NSCLC should include BRAF, mesenchymal epithelial transition factor receptor (MET), rearranged during transfection (RET), Human Epidermal Growth Factor Receptor 2 (HER2), neurotrophic tropomyosin receptor kinase (NTRK), and Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) for cases in which the common oncogenic drivers (EGFR, anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) are negative and whenever an adequate technique is available (42). Here, ALK is linked to non-small cell lung carcinoma.